Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has announced a multi-year strategic collaboration with Novartis to transform cancer care through proprietary AI-powered workflows. The partnership focuses on developing solutions within the Viz Oncology Suite to improve identification and stratification of patients with prostate and breast cancers, accelerating access to guideline-based precision treatments.
The collaboration addresses critical inefficiencies in cancer care, where fragmented systems, manual reviews, and complex care journeys often lead to delayed diagnoses and missed opportunities for life-extending therapies. According to the companies, these delays can result in worse patient outcomes, making timely intervention crucial for cancer patients.
Strategic Partnership Details
"We are excited to be partnering with Novartis, an innovative medicines company and a leader in oncology, to accelerate access to timely, guideline-based care for patients facing prostate and breast cancer," said Chris Mansi, MD, CEO and co-founder of Viz.ai. "This collaboration is part of our broader strategic expansion into oncology, furthering Viz.ai's mission to fundamentally transform healthcare through intelligent care coordination."
Rodney Gillespie, Head of Oncology at Novartis US, emphasized the importance of early intervention: "Earlier diagnosis and interventions can positively impact patient outcomes. At Novartis, we lead the industry in fostering bold partnerships and initiatives that support early screening and diagnosis; we are also leveraging innovative, data-driven technologies to help connect patients with appropriate care as quickly as possible."
Two New AI-Powered Solutions
The collaboration will produce two specialized AI solutions targeting specific cancer care challenges:
Viz Prostate Cancer
This solution is designed to streamline the identification of eligible patients for guideline-based treatment and support timely referrals to appropriate specialists. The need for such a system is underscored by concerning statistics: only one in four patients receives guideline-recommended therapy for prostate cancer, and thousands of patients with advanced disease who are eligible for potential life-extending treatments are never identified.
Viz Breast Cancer
The breast cancer solution aims to support oncologists by automating patient review, aggregating risk-relevant data, surfacing therapeutic guidelines, and facilitating coordination among multidisciplinary care teams. This addresses the complexity of breast cancer care, as it represents the most widely diagnosed cancer in the United States, with patient care journeys that are often fragmented and time-consuming.
Clinical Impact and Expert Perspective
Ethan M. Basch, MD, Chief of Oncology and Cancer Hospital Physician-in-Chief at UNC, highlighted the broader implications of AI in cancer care: "Too often, patients with cancer are identified late or fall through the cracks of an increasingly complex care system. AI-powered tools bring the potential to optimize how we detect, triage, and treat cancer—by delivering the right care, to the right patient, at the right time."
Company Background and Expansion
This oncology expansion builds on Viz.ai's established presence in AI-powered healthcare solutions. The company currently serves over 1,700 hospitals and health systems across the U.S. and Europe through its AI-powered Viz.ai One® platform, which focuses on increasing the speed of diagnosis and care coordination.
The collaboration represents a significant strategic move for Viz.ai as it extends its intelligent care coordination capabilities into oncology, aiming to create a connected healthcare AI layer that delivers improved care for patients across different medical specialties.
